[Phase II study of UFT in cancer of the uterine cervix].
UFT Phase II study was undertaken as a joint research project at 6 institutions on 36 patients with cancer of the uterine cervix. Results showed that, in the 25 of 36 cases in whom results and conclusions were feasible, there was an effectiveness of 16% (CR 3 cases, PR 1 case, NC 17 cases, PD 4 cases). Histologically, there was 25% effectiveness with large-cell, non-keratinizing, epidermoid carcinoma, against 16.7% with small-cell type. Considerable effect was noted as to metastasis effect in terms of location: Virchow 50%, and lungs 33.3%. CR effectiveness was noted in one case of local recurrence following irradiation. In 10 (37%) of the 27 evaluable cases some side effects were observed. Virtually all involved the digestive organs, and serious bone-marrow problems, hepatic or renal impairment were not evident. The findings suggested that UFT is an effective chemotherapeutic agent against carcinoma of the uterine cervix.
D000230:Adenocarcinoma / Q000188:drug therapy / Q000473:pathology; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000473:pathology; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008875:Middle Aged; D005641:Tegafur / Q000627:therapeutic use; D014498:Uracil / Q000627:therapeutic use; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy* / Q000473:pathology
D005641:Tegafur; D014498:Uracil